Profile
| Metric | Value |
|---|---|
| Full Name | Boston Scientific Corporation |
| Ticker | NYSE: BSX |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Medical Devices |
| Country | United States |
| IPO | |
| Indexes | |
| Website | bostonscientific.com |
| Employees | 53,000 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $94.14 | |
| Price, 1D Change | -1.65% | |
| Market Cap | $140B | |
| - | ||
| PE Ratio | 50.35 | |
| Beta | 0.68 | |
| Revenue | $17B | |
| Revenue, 1Y Change | +17.61% | |
| EPS | $1.25 | |
| EPS, 1Y Change | +16.25% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $1.25 | |
| EPS Estimate | $3.03 | |
| EPS Est. Change | +143.28% | |
| Revenue | $16.75B | |
| Revenue Estimate | $20.07B | |
| Revenue Est. Change | +19.84% | |
| Current Price | $94.14 | |
| Price Target | - | $127.00 |
| Price Tgt. Change | - | +34.91% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.01 | $1.07 | -46.63% | |
| $2.46 | $1.25 | -49.38% | |
| $3.03 | N/A | +143.28% | |
| $3.47 | N/A | +178.23% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $14.11B | $14.24B | +0.92% | |
| $16.60B | $16.75B | +0.88% | |
| $20.07B | N/A | +19.84% | |
| $22.38B | N/A | +33.65% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -0.50% | |
| Price, 3Y | +102.32% | |
| Market Cap, 1Y | +0.04% | |
| Market Cap, 3Y | +109.25% | |
| Revenue, 1Y | +17.61% | |
| Revenue, 3Y | +40.87% | |
| EPS, 1Y | +16.25% | |
| EPS, 3Y | +81.53% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $94.14 | |
| SMA 200 | $100.74 | |
| SMA 200 vs Price | +7.01% | |
| SMA 50 | $97.55 | |
| SMA 50 vs Price | +3.63% | |
| Beta | 0.68 | |
| ATR | $1.96 | |
| 14-Day RSI | 40.93 | |
| 10-Day Volatility | 20.69% | |
| 1-Year Volatility | 23.70% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $16.75B | |
| EPS | $1.25 | |
| Gross Profit | $11.46B | |
| Gross Margin | 68.41% | |
| Operating Profit | $3.00B | |
| Operating Margin | 17.93% | |
| Net Income | $1.85B | |
| Net Margin | 11.07% | |
| EBITDA | $3.44B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.49 | |
| Current Ratio | 1.08 | |
| Quick Ratio | 0.64 | |
| - | ||
| F-Score | 7 | |
| Altman Z-Score | 5.57 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 50.35 | |
| PS Ratio | 7.21 | |
| PB Ratio | 5.97 | |
| EV/EBITDA | 31.30 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $21.77B | |
| Cash & Equivalents | $414.00M | |
| Total Assets | $39.40B | |
| Current Assets | $6.92B | |
| Total Liabilities | $17.39B | |
| Current Liabilities | $6.40B | |
| Total Debt | $11.23B | |
| Short Term Debt | $1.78B | |
| Accounts Payable | $960.00M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $13.75B | |
| Operating Expenses | $8.46B | |
| Cost Of Goods Sold | $5.29B | |
| SG&A | $5.98B | |
| D&A | $1.27B | |
| Interest Expense | $0.00 | |
| Income Tax | $436.00M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $3.44B | |
| CFI | -$5.69B | |
| CFF | $1.81B | |
| Capex | $1.07B | |
| Free Cash Flow | $2.37B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Truist Securities | → | |
| RBC Capital | → | |
| Canaccord Genuity | → | |
| BTIG | → | |
| Wells Fargo | → | |
| UBS | → | |
| Truist Securities | → | |
| Morgan Stanley | → | |
| Canaccord Genuity | → | |
| BTIG | → |
Analyst sentiment
Institutional ownership
Screeners with BSX
Data Sources & References
- BSX Official Website www.bostonscientific.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/885725/000088572525000011/0000885725-25-000011-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- BSX Profile on Yahoo Finance finance.yahoo.com/quote/BSX
- BSX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/bsx
FAQ
What is the ticker symbol for Boston Scientific Corporation?
The ticker symbol for Boston Scientific Corporation is NYSE:BSX
Does Boston Scientific Corporation pay dividends?
No, Boston Scientific Corporation does not pay dividends
What sector is Boston Scientific Corporation in?
Boston Scientific Corporation is in the Healthcare sector
What industry is Boston Scientific Corporation in?
Boston Scientific Corporation is in the Medical Devices industry
What country is Boston Scientific Corporation based in?
Boston Scientific Corporation is headquartered in United States
When did Boston Scientific Corporation go public?
Boston Scientific Corporation initial public offering (IPO) was on May 19, 1992
Is Boston Scientific Corporation in the S&P 500?
Yes, Boston Scientific Corporation is included in the S&P 500 index
Is Boston Scientific Corporation in the NASDAQ 100?
No, Boston Scientific Corporation is not included in the NASDAQ 100 index
Is Boston Scientific Corporation in the Dow Jones?
No, Boston Scientific Corporation is not included in the Dow Jones index
When was Boston Scientific Corporation last earnings report?
Boston Scientific Corporation's most recent earnings report was on October 22, 2025
When does Boston Scientific Corporation report earnings?
The next expected earnings date for Boston Scientific Corporation is February 4, 2026